Checkpoint inhibitor-induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma

Leuk Lymphoma. 2020 Jan;61(1):228-230. doi: 10.1080/10428194.2019.1658104. Epub 2019 Sep 10.

Authors

Rohit Thummalapalli¹, Laura A Sena², John C Probasco³, Douglas E Gladstone²

Affiliations

¹ Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
² Department of Medical Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
³ Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

PMID: 31502489
DOI: 10.1080/10428194.2019.1658104

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Bone Marrow Transplantation*
Encephalitis
Hashimoto Disease / chemically induced
Hashimoto Disease / drug therapy*
Hodgkin Disease* / complications
Hodgkin Disease* / therapy
Humans
Immune Checkpoint Inhibitors / adverse effects*
Male
Rituximab / therapeutic use*

Substances

Immune Checkpoint Inhibitors
Rituximab

Supplementary concepts

Hashimoto's encephalitis